Inflammatory EPidermal GENodermatoses research hub

GENEPID: A 44-weeks monocentric open study assessing the efficacy and safety of Deucravacitinib in adults with Inflammatory EPidermal GENodermatoses (epidermolysis bullosa simplex and inflammatory congenital ichthyoses)

This study is testing a medicine called deucravacitinib for adults with rare, inherited inflammatory skin conditions. Researchers want to see if this treatment can calm skin inflammation, ease pain and itching, and improve everyday comfort and quality of life over a 44-week period.